Ted Pharmaceuticals (03880) has received approval from the China Securities Regulatory Commission for its H-share full circulation plan application.

The Wisdom Finance App reports that Ted Pharmaceuticals (03880) has announced that the China Securities Regulatory Commission has accepted the application from a specific shareholder of the company to submit a proposal to implement full circulation of H shares to the China Securities Regulatory Commission. According to the relevant application documents, the company has applied to convert 68,201,112 shares held by the shareholder with a par value of RMB 1.0 per share to H shares with a par value of RMB 1.0 per share. These shares account for approximately 48.10% of the total issued share capital of the company as of the date of this announcement.